Sequential Doxorubicin and Docetaxel as First-Line Treatment in Metastatic Breast Cancer: A GEICAM-9801 Phase II Study

被引：0
|
作者：
E. Alba
N. Ribelles
A. Antón
R. Pérez-Carrión
J.M. López-Vega
M. Llanos
A. Pelegri
J. Florián
M. Menéndez
M.J. Godes
机构：
[1] Hospital Clínico Universitario,
[2] Hospital Miguel Servet,undefined
[3] Hospital de la Princesa,undefined
[4] Hospital Valdecilla,undefined
[5] Hospital Universitario de Canarias,undefined
[6] Hospital Sant Joan de Reus,undefined
[7] Hospital Barbastro,undefined
[8] C Hospitalario de Santiago,undefined
[9] Hospital General Universitario,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 77卷
关键词：
first-line chemotherapy; metastatic breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. To evaluate the efficacy and the toxicity profile of the sequential administration of doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).
引用
收藏
页码：1 / 8
页数：7
相关论文
共 50 条
  • [31] Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer
    Baltali, E
    Altundag, MK
    Güler, N
    Özisik, Y
    Firat, D
    Baran, I
    Tekuzman, G
    TUMORI, 2002, 88 (03) : 200 - 203
  • [32] Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study
    de la Haba-Rodriguez, Juan
    Gonzalez Mancha, Rosario
    Perez Manga, Gumersindo
    Aranda Aguilar, Enrique
    Baena Canada, Jose Manuel
    Sanchez Rovira, Pedro
    Alba Conejo, Emilio
    CLINICAL BREAST CANCER, 2010, 10 (04) : 313 - 317
  • [33] Phase II study of vinorelbine and capecitabine as first-line treatment for metastatic breast cancer.
    El-Sadda, Wael
    Halim, Inas Ibraheim Abdel
    Aziz, Mohamed Abdel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] A phase II study of carboplatin and doxorubicin as the first-line treatment of ovarian cancer
    Tjuiandin, S.
    Chitia, L.
    Tryakin, A.
    Stenina, M.
    Panichenko, I.
    Zhordania, K.
    Garin, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 130 - 130
  • [35] Phase I study of liposomal doxorubicin (Caelix) and docetaxel as first line treatment in patients with metastatic breast cancer.
    Morabito, A
    Fanelli, M
    Gilberti, S
    Vitale, S
    Arena, MG
    Biondi, E
    Gattuso, D
    Massidda, B
    Gasparini, G
    ANNALS OF ONCOLOGY, 2000, 11 : 42 - 42
  • [36] Phase I study of liposomial doxorubicin (Caelix) and docetaxel as first line treatment in patients with metastatic breast cancer.
    Gasparini, G
    Morabito, A
    Fanelli, M
    Gilberti, S
    Vitale, S
    Arena, MG
    Biondi, E
    Gattuso, D
    Massidda, B
    ANNALS OF ONCOLOGY, 2000, 11 : 28 - 28
  • [37] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
  • [38] Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
    Vasey, PA
    Roché, H
    Bisset, D
    Terret, C
    Vernillet, L
    Riva, A
    Ramazeilles, C
    Azli, N
    Kaye, SB
    Twelves, CJ
    BRITISH JOURNAL OF CANCER, 2002, 87 (10) : 1072 - 1078
  • [39] Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
    P A Vasey
    H Roché
    D Bisset
    C Terret
    L Vernillet
    A Riva
    C Ramazeilles
    N Azli
    S B Kaye
    C J Twelves
    British Journal of Cancer, 2002, 87 : 1072 - 1078
  • [40] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results
    Gennatas, C. G.
    Michalaki, V.
    Gennatas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345